CA3205464A1 - Traitement de lymphocytes infiltrant les tumeurs - Google Patents

Traitement de lymphocytes infiltrant les tumeurs

Info

Publication number
CA3205464A1
CA3205464A1 CA3205464A CA3205464A CA3205464A1 CA 3205464 A1 CA3205464 A1 CA 3205464A1 CA 3205464 A CA3205464 A CA 3205464A CA 3205464 A CA3205464 A CA 3205464A CA 3205464 A1 CA3205464 A1 CA 3205464A1
Authority
CA
Canada
Prior art keywords
tumor
tils
population
expansion
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3205464A
Other languages
English (en)
Inventor
Ryan Guest
Joanne MCCAFFREY
John LEGALL
Zachary Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instil Bio UK Ltd
Original Assignee
Instil Bio UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instil Bio UK Ltd filed Critical Instil Bio UK Ltd
Publication of CA3205464A1 publication Critical patent/CA3205464A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des méthodes d'isolement et de cryoconservation de lymphocytes infiltrant les tumeurs (TIL) et de production de populations thérapeutiques de TIL, comprenant des méthodes par l'utilisation d'un kit et d'un dispositif semi-automatique pour la désagrégation, l'enrichissement et la cryoconservation aseptiques d'une tumeur réséquée avant l'expansion de la population TIL. La présente invention concerne également des méthodes d'expansion et/ou de stabilisation de TIL, par exemple des UTIL, des compositions les comprenant et des méthodes de traitement les mettant en jeu.
CA3205464A 2020-12-18 2021-12-16 Traitement de lymphocytes infiltrant les tumeurs Pending CA3205464A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063127639P 2020-12-18 2020-12-18
US202063127582P 2020-12-18 2020-12-18
US63/127,582 2020-12-18
US63/127,639 2020-12-18
US202163288409P 2021-12-10 2021-12-10
US202163288414P 2021-12-10 2021-12-10
US63/288,409 2021-12-10
US63/288,414 2021-12-10
PCT/IB2021/000883 WO2022130017A2 (fr) 2020-12-18 2021-12-16 Traitement de lymphocytes infiltrant les tumeurs

Publications (1)

Publication Number Publication Date
CA3205464A1 true CA3205464A1 (fr) 2022-06-23

Family

ID=80628849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3205464A Pending CA3205464A1 (fr) 2020-12-18 2021-12-16 Traitement de lymphocytes infiltrant les tumeurs

Country Status (5)

Country Link
EP (1) EP4263808A2 (fr)
JP (1) JP2023554425A (fr)
AU (1) AU2021404204A1 (fr)
CA (1) CA3205464A1 (fr)
WO (1) WO2022130017A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
AU2020408017A1 (en) 2019-12-20 2022-07-14 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
WO2024143453A1 (fr) * 2022-12-28 2024-07-04 インターステム株式会社 Composition cellulaire

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
CN1322137C (zh) 1997-12-22 2007-06-20 牛津生物医学（英国）有限公司 基于马传染性贫血病毒(eiav)的逆转录病毒载体
US6706289B2 (en) 2000-10-31 2004-03-16 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
IL295201A (en) 2010-11-12 2022-10-01 Nektar Therapeutics Conjugations of a part of il-2 and a polymer, preparations containing them and their uses
RU2671897C2 (ru) 2013-03-01 2018-11-07 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
CN106574244B (zh) 2014-06-11 2022-01-07 保利比奥斯博特有限责任公司 用细胞因子组合物扩增淋巴细胞用于主动细胞免疫治疗
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
JOP20190224A1 (ar) * 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
GB201801067D0 (en) 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
MX2020010264A (es) * 2018-03-29 2020-11-06 Iovance Biotherapeutics Inc Procesos para la produccion de linfocitos infiltrantes en tumor y usos de los mismos en inmunoterapia.
WO2019210131A1 (fr) * 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
GB201810181D0 (en) 2018-06-21 2018-08-08 Immetacyte Ltd Cells expressing chimeric recominant growth factor receptors
GB201900858D0 (en) 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
JP2022522793A (ja) 2019-03-01 2022-04-20 アシンプトート リミテッド 閉じた組織分離および冷凍保存
AU2020408017A1 (en) 2019-12-20 2022-07-14 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof

Also Published As

Publication number Publication date
WO2022130017A3 (fr) 2022-07-28
JP2023554425A (ja) 2023-12-27
EP4263808A2 (fr) 2023-10-25
WO2022130017A2 (fr) 2022-06-23
AU2021404204A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
US11767510B2 (en) Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
TWI831776B (zh) 腫瘤浸潤性淋巴細胞之基因編輯和彼於免疫治療之用途
KR102296580B1 (ko) 엔드-투-엔드 세포 요법의 자동화
AU2018234640B2 (en) Methods for cryogenic storage
CA3205464A1 (fr) Traitement de lymphocytes infiltrant les tumeurs
EP4262828A1 (fr) Lymphocytes infiltrant les tumeurs et agents thérapeutiques anti-cd47
CA3205462A1 (fr) Traitement de lymphocytes infiltrant les tumeurs
US20240197785A1 (en) Processing of tumor infiltrating lymphocytes
TW202237828A (zh) 腫瘤浸潤淋巴細胞之處理
AU2022409848A1 (en) Processing of tumor infiltrating lymphocytes
WO2022271881A1 (fr) Méthodes d'isolement de lymphocytes infiltrant les tumeurs et leur utilisation
TW202242100A (zh) 腫瘤浸潤淋巴細胞之處理
TW202136502A (zh) 用於分離腫瘤浸潤淋巴細胞之裝置及方法及其用途
KR20210148197A (ko) 면역 세포 제공 방법
Stroncek et al. CAR T-Cell: Cell Processing Laboratory Considerations
WO2023200929A1 (fr) Compositions de lymphocytes infiltrant les tumeurs (til) et leurs utilisations
WO2023200928A1 (fr) Procédés d'identification de répertoire de tcr et compositions et utilisations associées
Koepsell et al. Successful “in-flight” activation of natural killer cells during long-distance shipping_3695